1. TRH increases cerebrospinal fluid concentration of kynurenine.
- Author
-
Takeuchi Y, Matsushita H, Kawano H, Sakai H, Yoshimoto K, and Sawada T
- Subjects
- Adolescent, Anticonvulsants therapeutic use, Child, Child, Preschool, Electrodes, Epilepsy drug therapy, Female, Humans, Infant, Male, Receptors, N-Methyl-D-Aspartate antagonists & inhibitors, Spasms, Infantile cerebrospinal fluid, Spasms, Infantile drug therapy, Thyrotropin-Releasing Hormone therapeutic use, Tryptophan cerebrospinal fluid, Tryptophan metabolism, Tyrosine cerebrospinal fluid, Tyrosine metabolism, Up-Regulation, Anticonvulsants pharmacology, Epilepsy cerebrospinal fluid, Kynurenine cerebrospinal fluid, Thyrotropin-Releasing Hormone pharmacology
- Abstract
We have analyzed changes in cerebrospinal fluid (CSF) concentrations of monoamine-related substances to clarify the mechanism of the antiepileptic action of thyrotropin-releasing hormone (TRH). TRH-tartrate was administered to 14 patients with intractable epilepsy. Before and 2 weeks after TRH administration, CSF was collected and analyzed for tryptophan and tyrosine metabolites. Among monoamine-related substances, only CSF concentrations of kynurenine were increased after TRH therapy. Considering the fact that kynurenic acid acts as antagonist on the NMDA receptor complex, the results of this study may explain at least one of the mechanisms of the effectiveness of TRH therapy for intractable epilepsy.
- Published
- 1999
- Full Text
- View/download PDF